Angel Montero Carcaboso

Angel Montero Carcaboso

Jefe de Grupo Senior

BS Pharm (1999) and PhD (2004) Universidad del País Vasco -Euskal Herriko Unibertsitatea. MBA (2003) UNED. Postdoctoral fellow in UBA (2004-2008) and Saint Jude Children's Research Hospital (2008-2010).

Dr Carcaboso holds a wide pharmaceutical background. He has performed multidisciplinary and translational work in the field of pediatric oncology. He has shown, together with his colleagues at SJD and his former institutions, success to develop innovative projects, even advanced therapies, for children with cancer. They have achieved clinical trials and international acknowledgement of their work.

The laboratory puts high effort to develop patient-derived tumor cell models and xenografts ("HSJD models"). Because this work is devoted to the families of children with cancer, the lab takes special care, as they request, of sharing all the resources generated mostly through their generosity. Consequently, the lab has shared cells and xenografts established at SJD with more than 60 research institutions worldwide. All these institutions focus in finding cures for children with cancer. These international collaborations position the laboratory among the most influential institutions in preclinical research of pediatric cancer in the world.

Selected publications

[1] H. Castillo-Ecija, C. Monterrubio, [...], A.M. Carcaboso, Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution, J Control Release 324 (2020) 440-449.

[2] G. Pascual-Pasto, [...], A.M. Carcaboso, Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01, Sci Transl Med 11(476) (2019).

[3] C. Monterrubio, [...], A.M. Carcaboso, Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8, J Control Release 255 (2017) 108-119.

[4] G. Pascual-Pasto, [...], A.M. Carcaboso, Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination, Cancer Lett 380(1) (2016) 10-19.

[5] C. Monterrubio, [...], A.M. Carcaboso, SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery, Biomaterials 79 (2016) 69-78.

Last Publications

More Publications

Projects

Project name:
Contrato predoctoral de formación en investigación en salud_Beneficiario: Helena Castillo
Leader
Angel Montero Carcaboso
Funding entities:
Instituto de Salud Carlos III (ISCIII)
Code
FI19/00138
Starting - finishing date:
2020 - 2023
Project name:
Inhibition of the PI3K/Akt pathway in pediatric high grade and diffuse intrinsic pontine gliomas (pHGG/DIPG)
Leader
Angel Montero Carcaboso
Funding entities:
Fundació La Marató de TV3
Code
201927-30
Starting - finishing date:
2020 - 2023
Project name:
Gate2Brain-4-DIPG, a novel therapeutic strategy for the treatment of pediatric brain tumors using Gate2Brain technology.
Leader
Angel Montero Carcaboso
Funding entities:
Fundación Marcelino Botín
Code
PCP00287
Starting - finishing date:
2020 - 2022
More projects

News

See All news